CoChat
Sign Up
Cited by 402Atrial Fibrillation Management and OutcomesHeart Failure Treatment and ManagementAcute Myocardial Infarction Research

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad, Oldgren, Jonas, Andersson, Ulrika, Connolly, Stuart J., Ezekowitz, Michael D., Hohnloser, Stefan H., Reilly, Paul A., Vinereanu, Dragos, Siegbahn, Agneta, Yusuf, Salim, Wallentin, Lars·2012·Circulation
DOI 10.1161/circulationaha.111.038729
Open this paper in CoChat — free account

Abstract

BACKGROUND: Cardiac biomarkers are strong predictors of adverse outcomes in several patient populations. We evaluated the prevalence of elevated troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and their association to cardiovascular events in atrial fibrillation (AF) patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. METHODS AND RESULTS: Biomarkers at randomization were analyzed in 6189 patients. Outcomes were evaluated by Cox proportional hazards models adjusting for established cardiovascular risk factors and the CHADS(2) and CHA(2)DS(2)-VASc risk scores. Patients were stratified based on troponin I concentrations: <0.010 μg/L, n=2663; 0.010 to 0.019 μg/L, n=2006; 0.020 to 0.039 μg/L, n=1023; ≥0.040 μg/L, n=497; and on NT-proBNP concentration quartiles: <387; 387 to 800; 801 to 1402; >1402 ng/L. Rates of stroke were independently related to levels of troponin I with 2.09%/year in the highest and 0.84%/year in the lowest troponin I group (hazard ratio [HR], 1.99 [95% CI, 1.17-3.39]; P=0.0040), and to NT-proBNP with 2.30%/year versus 0.92% in the highest versus lowest NT-proBNP quartile groups, (HR, 2.40 [95% CI, 1.41-4.07]; P=0.0014). Vascular mortality was also independently related to biomarker levels with 6.56%/year in the highest and 1.04%/year the lowest troponin I group (HR, 4.38 [95% CI, 3.05-6.29]; P<0.0001), and 5.00%/year in the highest and 0.61%/year in the lowest NT-proBNP quartile groups (HR, 6.73 [3.95-11.49]; P<0.0001). Biomarkers increased the C-statistic from 0.68 to 0.72, P<0.0001, for a composite of thromboembolic events. CONCLUSIONS: Elevations of troponin I and NT-proBNP are common in patients with AF and independently related to increased risks of stroke and mortality. Cardiac biomarkers seem useful for improving risk prediction in AF beyond currently used clinical variables.

Overview

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.038729

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Cited by

Sorted by citations

Items 301–400 of 400

Related

See all

Metadata

Authors
Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Vinereanu, D., Siegbahn, A., Yusuf, S., & Wallentin, L.
Affiliations
  • Goethe University Frankfurt (DE)
  • From the Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden (Z.H., J.O., L.W.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (U.A.); Population Health Research Institute, Hamilton, Canada (S.J.C., S.Y.); Lankenau Institute for Medical Research and the Heart Center, Wynnewood, PA (M.D.E.); Department of Cardiology, J.W. Goethe University, Frankfurt, Germany (S.H.H.); Boehringer Ingelheim Pharmaceuticals,...
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2012-04-03
Volume
125
Issue
13
Pages
1605-1616
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/circulationaha.111.038729
OpenAlex
W1972837977
Cited by
402
References
48
Citations by year
2026: 11 · 2025: 23 · 2024: 19 · 2023: 20 · 2022: 17 · 2021: 19 · 2020: 31 · 2019: 31 · 2018: 26 · 2017: 31 · 2016: 43 · 2015: 29 · 2014: 31 · 2013: 60 · 2012: 11
FWCI
26.96
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
atrial fibrillation, cardiac biomarkers, troponin I, NT-proBNP, stroke risk, vascular death, RE-LY trial, anticoagulation, CHA2DS2-VASc score, CHADS2 score, cardiovascular risk stratification, biomarker thresholds, risk prediction model, bleeding risk, warfarin, direct oral anticoagulants
MeSH terms
Aged, Anticoagulants, Atrial Fibrillation, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Peptide Fragments, Prospective Studies, Risk Factors, Cohort Studies, Biomarkers, Treatment Outcome, Troponin I, Natriuretic Peptide, Brain, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review